The biotechnology company Modern entered into ‘red numbers’ by losing 4,714 million dollars (4,358 million euros) in 2023, compared to the profits of 8,362 million dollars (7,731 million euros) that it earned the previous year.
The results published by the company also show that, with regard to the billingthe firm reached 6,848 million dollars (6,331 million euros), 64.4% less. From the laboratory they have indicated that the drop in billing is mainly due to the lower sale of vaccines against Covid-19.
The company has increased its research and development expenses in 2023, until reaching 4,845 million dollars (4,479 million euros), which becomes the main cost item. Then, taking into account the production costs and sales costsgeneral and administrative services totaled 11,087 million dollars (10,250 million euros), 12.6% more.
Regarding the fourth trimesterModern earned 217 million dollars (200.6 million euros), 85.2% less than the profits of 1,465 million dollars (1,354 million euros) for the same equivalent period. For its part, turnover fell 44.7%, to 2,811 million dollars (2,599 million euros).
“2023 was a year of transition for Moderna, since we adapt to an endemic market. At the same time, our development team made significant pipeline advancements in infectious diseases, oncology and rare diseases, and our commercial team increased Covid-19 market share in the United States,” he said. explained the CEO of Moderna, Stéphane Bancel. The manager has anticipated the approval during the first half of 2024 of vaccines to prevent respiratory syncytial virus.
2024-02-23 07:47:10
#Moderna #enters #red #numbers #losing #million #euros #due #drop #anticovid #vaccines
